Risk stratification of a novel non-invasive fibrosis score in metabolic dysfunction-associated steatotic liver disease

Key Points

• The novel fibrosis score effectively stratifies risk for metabolic dysfunction-associated steatotic liver disease, enhancing patient management.
• Key metrics indicate improvements in accuracy over traditional methods with a sensitivity of 85% and specificity of 90%.
• Assessment using a cohort of adults with liver conditions highlights the potential for broader application in clinical practice.
• This findings may enable early intervention strategies, yet further studies are needed for external validation.